Gilgamesh Announces Clinical Candidates For Two Programs With First In Human Dosing to Begin in Late 2022

 Gilgamesh Pharmaceuticals has announced the nomination of two lead clinical candidates for the treatment of debilitating neuropsychiatric disorders such as depression, anxiety, PTSD, and substance use disorders

Category Press Release
Published in Biospace

Companies Featured

Gilgamesh
Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for mental health disorders.